Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery

American Journal of Health-System Pharmacy

Volumn 64, Issue 22, 2007, Pages 2349-2355

  Shorr, Andrew F ^a,b   Sarnes, Matt W ^c,f   Peeples, Patricia J ^c,f   Stanford, Richard H ^d   Happe, Laura E ^e,f   Farrelly, Eileen ^e,f  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c XCENDA   (United States)

^d GLAXOSMITHKLINE   (United States)

^e Xcenda   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Anticoagulants; Costs; Dalteparin; Drug comparisons; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Surgery; Thromboembolism; Toxicity

Indexed keywords

DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; VENOUS THROMBOEMBOLISM;

EID: 36448935264     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070178     Document Type: Article

References (31)

1. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003; 107(23, suppl 1):I9-16.
2. White RH. The epidemiology of venous thromboembolism. Circulation. 2003; 107(23, suppl 1):I4-8.
3. Heit JA, Cohen AT, Anderson FA, on behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal venous thromboembolism (VTE) events in the US. Blood. 2005; 106:267a. Abstract.
4. Anderson FA Jr, Wheeler HB, Goldberg RJ et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med. 1991; 151:933-8.
5. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Chest. 2001; 119(suppl):132S-175S.
6. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(suppl):338S-400S.
7. McGart GM, Kayser SR. Therapeutic equivalency of low-molecular-weight heparins. Ann Pharmacother. 2002; 36:1042-57.
8. Eriksson BI, Kalebo P, Anthymyr BA et al. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am. 1991; 73:484-93.
9. Buller HR, Davidson BL, Decousus H et al., for the Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2004; 349:1695-702.
10. Eriksson BI, Bauer KA, Lassen MR et al., for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001; 345:1298-304.
11. Lassen MR, Bauer KA, Eriksson BI et al., for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002; 359:1715-20.
12. Bauer KA, Eriksson BI, Lassen MR et al., for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001; 345:1305-10.
13. Turpie AG, Bauer KA, Eriksson BI et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002; 162:1833-40.
14. Shorr AF, Kwong LM, Sarnes M et al. Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis. Thromb Res. In press.
15. Lindenauer PK, Pekow P, Wang K et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med. 2005; 353:349-61.
16. Ouriel K, Kaul AF, Leonard MC. Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis. J Vasc Surg. 2004; 40:971-7.
17. Orrick JJ, Segal R, Johns TE et al. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to Infectious Diseases Society of America guidelines. Pharmacoeconomics. 2004; 22:751-7.
18. Blanchette C, Wang P, Joshi A et al. Cost and utilization of blood transfusion associated with spinal surgeries in the United States. Eur Spine J. 2007; 16:353-63.
19. Blanchette CM, Wang PF, Joshi AV et al. Resource utilization and costs of blood management services associated with knee and hip surgeries in US hospitals. Adv Ther. 2006; 23:54-67.
20. Stanford R, McLaughlin T, Okamoto LJ. The cost of asthma in the emergency department and hospital. Am J Respir Crit Care Med. 1999; 160:211-5.
21. Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest. 2003; 124(suppl):386S-392S.
22. White RH, Romano PS, Zhou H et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998; 158:1525-31.
23. White RH, Zhou H, Romano PS. Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism. Arch Intern Med. 1998; 158:1005-10.
24. Bjørnarå BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br. 2006; 88:386-91.
25. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40:373-83.
26. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45:613-9.
27. Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy. 2004; 9:197-204.
28. Dodd S, Bassi A, Bodger K et al. A comparison of multivariable regression models to analyze cost data. J Eval Clin Pract. 2006; 12:76-86.
29. Oster G, Ollendorf DA, Vera-Llonch M et al. Economic consequences of venous thromboembolism following major orthopedic surgery. Ann Pharmacother. 2004; 38:377-82.
30. Vera-Llonch M, Hagiwara M, Oster G. Clinical and economic consequences of bleeding following major orthopedic surgery. Thromb Res. 2006; 117:569-77.
31. MedQIC. SCIP Project information. www.medqic.org/scip (accessed 2007 Sep 4).